These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Rho kinase inhibition by fasudil ameliorates diabetes-induced microvascular damage. Arita R; Hata Y; Nakao S; Kita T; Miura M; Kawahara S; Zandi S; Almulki L; Tayyari F; Shimokawa H; Hafezi-Moghadam A; Ishibashi T Diabetes; 2009 Jan; 58(1):215-26. PubMed ID: 18840783 [TBL] [Abstract][Full Text] [Related]
9. Rho kinase inhibition by fasudil suppresses lipopolysaccharide-induced apoptosis of rat pulmonary microvascular endothelial cells via JNK and p38 MAPK pathway. Liu H; Chen X; Han Y; Li C; Chen P; Su S; Zhang Y; Pan Z Biomed Pharmacother; 2014 Apr; 68(3):267-75. PubMed ID: 24406296 [TBL] [Abstract][Full Text] [Related]
10. The Rho kinase inhibitor fasudil augments the number of functional endothelial progenitor cells in ex vivo cultures. O E; Ahn HY; Kim HK; You JC; Shin JC; Joe YA Int J Mol Med; 2011 Sep; 28(3):357-63. PubMed ID: 21567077 [TBL] [Abstract][Full Text] [Related]
11. Fasudil inhibits lysophosphatidic acid-induced invasiveness of human ovarian cancer cells. Ogata S; Morishige K; Sawada K; Hashimoto K; Mabuchi S; Kawase C; Ooyagi C; Sakata M; Kimura T Int J Gynecol Cancer; 2009 Dec; 19(9):1473-80. PubMed ID: 19955921 [TBL] [Abstract][Full Text] [Related]
12. Rho Kinase Inhibitor Fasudil Suppresses the Vasculogenic Mimicry of B16 Mouse Melanoma Cells Both In Vitro and In Vivo. Xia Y; Cai XY; Fan JQ; Zhang LL; Ren JH; Chen J; Li ZY; Zhang RG; Zhu F; Wu G Mol Cancer Ther; 2015 Jul; 14(7):1582-90. PubMed ID: 25934709 [TBL] [Abstract][Full Text] [Related]
13. Rho kinase inhibitor fasudil suppresses migration and invasion though down-regulating the expression of VEGF in lung cancer cell line A549. Zhu F; Zhang Z; Wu G; Li Z; Zhang R; Ren J; Nong L Med Oncol; 2011 Jun; 28(2):565-71. PubMed ID: 20300976 [TBL] [Abstract][Full Text] [Related]
14. The Rho kinase inhibitor fasudil inhibits tumor progression in human and rat tumor models. Ying H; Biroc SL; Li WW; Alicke B; Xuan JA; Pagila R; Ohashi Y; Okada T; Kamata Y; Dinter H Mol Cancer Ther; 2006 Sep; 5(9):2158-64. PubMed ID: 16985048 [TBL] [Abstract][Full Text] [Related]
15. Rho-kinase inhibitor, fasudil, suppresses glioblastoma cell line progression in vitro and in vivo. Deng L; Li G; Li R; Liu Q; He Q; Zhang J Cancer Biol Ther; 2010 Jun; 9(11):875-84. PubMed ID: 20364104 [TBL] [Abstract][Full Text] [Related]
16. Peptides derived from human decorin leucine-rich repeat 5 inhibit angiogenesis. Sulochana KN; Fan H; Jois S; Subramanian V; Sun F; Kini RM; Ge R J Biol Chem; 2005 Jul; 280(30):27935-48. PubMed ID: 15923192 [TBL] [Abstract][Full Text] [Related]
17. ROCK inhibitor fasudil attenuated high glucose-induced MCP-1 and VCAM-1 expression and monocyte-endothelial cell adhesion. Li H; Peng W; Jian W; Li Y; Li Q; Li W; Xu Y Cardiovasc Diabetol; 2012 Jun; 11():65. PubMed ID: 22694757 [TBL] [Abstract][Full Text] [Related]
18. Fasudil hydrochloride hydrate, a Rho-kinase (ROCK) inhibitor, suppresses collagen production and enhances collagenase activity in hepatic stellate cells. Fukushima M; Nakamuta M; Kohjima M; Kotoh K; Enjoji M; Kobayashi N; Nawata H Liver Int; 2005 Aug; 25(4):829-38. PubMed ID: 15998434 [TBL] [Abstract][Full Text] [Related]
19. RhoA/ROCK pathway inhibition by fasudil suppresses the vasculogenic mimicry of U2OS osteosarcoma cells in vitro. Xia Y; Cai X; Fan J; Zhang L; Li Z; Ren J; Wu G; Zhu F Anticancer Drugs; 2017 Jun; 28(5):514-521. PubMed ID: 28225457 [TBL] [Abstract][Full Text] [Related]
20. Inhibition of protein kinase C-mediated contraction by Rho kinase inhibitor fasudil in rabbit aorta. Shimomura E; Shiraishi M; Iwanaga T; Seto M; Sasaki Y; Ikeda M; Ito K Naunyn Schmiedebergs Arch Pharmacol; 2004 Nov; 370(5):414-22. PubMed ID: 15459803 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]